Advertisement

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

David A. Hyman, MD, JD, on Inclusive Shared Savings

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Nov
13
Today In Oncology
Underlying Mechanisms of Chemoresistance in AML
Exercise Training Improves Strength and Quality of Life for Patients With Metastatic Breast Cancer
Supportive Care: Most Clinic Staff Prefer People-Focused vs Digital Solutions
Addition of Eryaspase to Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
Longtime FDA Innovator Appointed as Director of CDER
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo